전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved11 programs
ADCLimited DatastaleRemeGenPreclinical

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin and Cisplatin)

Uterine Cervical Neoplasms · Uterine Cervical Neoplasms

#UterineCervicalNeoplasms#ADC#Preclinical#antibody-drug-conjugate#RemeGen
Trials 13Status Recruiting
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Phase 1

Autologous aPD-L1 armored anti-CD22 CAR T cells (Autologous aPD-L1 armored anti-CD22 CAR T cells)

Solid Tumor, Adult; Cervical Cancer · PD-L1

#PD-L1#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Active
AntibodyLimited DatastaleSamsung Medical CenterPhase 2

durvalumab (Imfinzi, BAVC-C+Durvalumab)

Cervical Cancer · Cervical Cancer

#CervicalCancer#Antibody#Phase2#monoclonal-antibody#Samsung
Trials 1Status Active
CGTLimited DatastaleShenzhen Geno-Immune Medical In…Phase 2

Cervical cancer-specific CAR-T cells (Cervical cancer-specific CAR-T cells)

Cervical Cancer · Cervical Cancer

#CervicalCancer#CGT#Phase2#cell-gene-therapy#CAR-T+2
Trials 1Status Active
AntibodyLimited DatastaleUniversitätsklinikum KölnPhase 2

Nivolumab/Ipilimumab (Concurrent Chemo-radio-immunotherapy, Concurrent Chemo-radio-immunotherapy (Nivolumab/Ipilimumab))

Cervical Cancer ≥ FIGO IIB and or Lymph Node Metastases · Cervical Cancer ≥ FIGO IIB and or Lymph

#CervicalCancerFIGOIIBandorLymph#Antibody#Phase2#monoclonal-antibody#CervicalCancerFIGOIIBandorLymphN+1
Trials 1Status Discontinued
ADCLimited DatastaleGenmabPhase 2

HuMax-AXL-ADC (Enapotamab vedotin, Enapotamab vedotin (HuMax-AXL-ADC))

Ovarian Cancer; Cervical Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase2#antibody-drug-conjugate#CervicalCancer+1
Trials 1Status Active
AntibodyLimited DatastaleUniversitätsklinikum KölnPhase 2

Nivolumab/Ipilimumab (Pre-Chemo-radio-immunotherapy Treatment, Pre-Chemo-radio-immunotherapy Treatment (Nivolumab/Ipilimumab))

Cervical Cancer ≥ FIGO IIB and or Lymph Node Metastases · Cervical Cancer ≥ FIGO IIB and or Lymph

#CervicalCancerFIGOIIBandorLymph#Antibody#Phase2#monoclonal-antibody#CervicalCancerFIGOIIBandorLymphN+1
Trials 1Status Discontinued
AntibodyLimited DatastaleZhejiang Cancer HospitalPhase 2

Recombinant human adenovirus type 5＋Camrelizumab (Recombinant human adenovirus type 5＋Camrelizumab)

Uterine Cervical Neoplasms; Oncolytic Virotherapy · Uterine Cervical Neoplasms

#UterineCervicalNeoplasms#Antibody#Phase2#monoclonal-antibody#OncolyticVirotherapy+1
Trials 1Status Active
AntibodyLimited DatastaleXencor, Inc.Phase 1

XmAb®22841 (XmAb®22841)

Melanoma; Cervical Carcinoma · Melanoma

#Melanoma#Antibody#Phase1#monoclonal-antibody#CervicalCarcinoma+1
Trials 1Status Active
AntibodyLimited DatastaleXencor, Inc.Phase 1

XmAb®23104 (XmAb®23104)

Melanoma (Excluding Uveal Melanoma); Cervical Carcinoma · HER2

#HER2#Antibody#Phase1#monoclonal-antibody#MelanomaExcludingUvealMelanoma+2
Trials 1Status Active
AntibodyLimited DatastaleBristol Myers SquibbPhase 1

ipilimumab (Yervoy®, Yervoy® (ipilimumab))

Melanoma (Excluding Uveal Melanoma); Cervical Carcinoma · HER2

#HER2#Antibody#Phase1#monoclonal-antibody#MelanomaExcludingUvealMelanoma+2
Trials 1Status Active